BioCentury
ARTICLE | Clinical News

ABT-894 misses diabetic neuropathic pain endpoint

February 12, 2009 2:10 AM UTC

NeuroSearch (CSE:NEUR) and Abbott (NYSE:ABT) discontinued development of ABT-894 for diabetic neuropathic pain after two parallel, double-blind, international Phase II trials missed the primary endpoi...